35): H1145-H1152, 1994.-Myocardial protection in the rabbit induced by ischemic preconditioning is thought to be adenosine receptor linked, but the signaling pathway responsible for the protection has yet to be identified. This study tests whether protein kinase C could be involved. Either of two inhibitors of protein kinase C, staurosporine (50 pg/kg) or polymyxin B (24 mg/kg), were administered to rabbits subjected to 30 min regional myocardial ischemia followed by 180 min reperfusion.
Half of the rabbits were preconditioned while the other half served as nonpreconditioned controls. Nonpreconditioned hearts without drug or treated with staurosporine or polymyxin B resulted in 37.8 t 3.1, 40.5 2 2.8, and 42.0 * 7.0%; infarction of the risk zone, respectively. Preconditioning limited infarct size to 7.3 + 2.7%. Both inhibitors blocked protection in preconditioned hearts with 36.2 2 2.7 and 40.9 t 2.5% of the risk zone infarcted, respectively. Activation of protein kinase C with 4p-phorbol 12-myristate 13-acetate (PMA) or with I-oleyl-2-acetyl glycerol (OAG) mimicked preconditioning in buffer-perfused hearts. PMA (0.01 nmol/min) or OAG (10 nmol/min) for 5 min was followed by 10 min of washout.
Infarct size after 30 min regional ischemia was limited in the PMA and OAG groups (6.4 * 1.4 and 11.7 2 3.3 vs. 28.0 t 4.5% in untreated controls) and was equipotent with ischemic preconditioning (11.8 * 2.2%). Polymyxin B also blocked protection from ischemic preconditioning in the isolated heart (33.0 * 5.0%). Because protein kinase C activity is required for the preconditioned heart to be protected and because pretreatment with protein kinase C activators mimic preconditioning, we conclude that protein kinase C is an important step in the mechanism of preconditioning. ischemic preconditioning; diacylglycerol; phorbol12-myristate 13-acetate; staurosporine; myocardial infarct ISCHEMIC PRECONDITIONING is a powerful method for limiting ischemia-induced tissue necrosis. Preconditioning was first described by Murry et al. (19) in 1986 and later was confirmed by numerous other researchers (15, 16, 18, 19, 21, 32) . In the rabbit the protection is apparently afforded by ischemia-induced adenosine release and subsequent activation of A1 adenosine receptors (17,29) . A1 adenosine receptors are usually coupled to pertussis toxin-sensitive G proteins, and after rabbits were pretreated with pertussis toxin preconditioning was no longer protective (28). Muscarinic (M2) receptor stimulation by carbachol mimics preconditioning in the rabbit (28), probably because it is coupled to the same pertussis toxin-sensitive G proteins (2, 7, 14) . G proteins are well recognized as essential signal transduction elements for the regulation of adenyl cyclase, K+ and Ca2+ channels, and phospholipases (2, 6, 7, 14) . Adenosine Al receptors in tissues including guinea pig myocardium have been reported to cause phospholipase C activation (13, 20, (22) (23) (24) . Phospholipase C activity leads to the production of two second messengers, diacylglycerol (DAG) and D-t?'tyO-inOSitO1 1,4,5-trisphosphate [Ins( 1,4,5)P3]. DAG is, in turn, an activator of protein kinase C (4, 10, 34). Protein kinase C modifies proteins within the cell by phosphorylating them.
The aim of this study was to investigate the possibility that stimulation of protein kinase C is involved in the protection afforded by preconditioning. The study consisted of two parts. The first aim of the study was to examine whether inhibition of protein kinase C by staurosporine (26) or polymyxin B (5) could block the protection of preconditioning. The second aim of the study was to examine whether exogenous activation of protein kinase C by a phorbol ester or a diacylglycerol analogue could mimic preconditioning and protect the heart against ischemia-induced necrosis.
MATERIALS AND METHODS

Surgical Preparation of Animals
New Zealand White rabbits of either sex, weighing between 1.35 and 2.5 kg, were used in this study. They were anesthetized with intravenous pentobarbital sodium (30 mglkg), which was administered via a marginal ear vein. The neck was opened with a ventral midline incision, and a tracheotomy was performed. The rabbits were ventilated with 100% oxygen via a positive-pressure respirator (MD Industries, Mobile, AL). Ventilation rate was 30-35 breaths/min, and tidal volume was -15 ml. The respiratory rate was adjusted to keep the blood pH in the physiological range.
In Situ Studies
Catheters filled with heparinized saline (10 U/ml) were placed in the left carotid artery and jugular vein to monitor blood pressure and inject drugs, respectively. Throughout the experiment additional anesthesia was also administered through the jugular vein as needed. A left thoracotomy was performed in the fourth intercostal space, and the pericardium was opened to expose the heart. A 2.0 silk suture was passed around a left coronary artery, and the ends of the silk suture were threaded through a small vinyl tube to form a snare. The coronary branch was occluded by pulling the snare, which was then fixed by clamping the tube with a mosquito hemostat. The presence of myocardial ischemia was confirmed by regional cyanosis and akinesis. Reperfusion was effected by releasing the snare and was confirmed by visible hyperemia over the surface. All hearts in the study were subjected to 30 min regional ischemia followed by 180 min reperfusion.
In Vitro Studies
Rabbits were anesthetized and ventilated as described above. The chest was opened, and a snare was placed around a marginal branch of the left coronary artery. The heart was then excised and quickly mounted on a Langendorff apparatus (60 s or less transfer time) and perfused under constant pressure (100 cmHZO) with a Krebs-Henseleit bicarbonate buffer containing glucose (10 mM) and calcium (2.4 mM). A fluid-filled latex balloon was inserted in the left ventricle. The balloon volume was adjusted to an end-diastolic pressure of 5-10 mmHg. All hearts experienced an initial 20-min stabilization period. Infarction was induced by 30 min of regional ischemia followed by 120 min of reperfusion.
Measurement of Infarct and Risk Area
The hearts from the in situ study were removed and mounted on a Langendorff apparatus at the end of the final reperfusion.
Hearts from the in vitro study were already on the apparatus at the end of the study. The silk suture under the coronary branch was tightly tied to occlude the artery, and a 0.5% suspension of fluorescent particles (l-10 pm diam, Duke Scientific, Palo Alto, CA) was infused into the perfusate. This differentiates the ischemic (risk) zone as the tissue with no fluorescence. The heart was then removed, weighed, and then frozen. The frozen heart was cut into transverse slices 2 mm thick. The slices were thawed and stained by incubation for 20 min in 1%: triphenyl tetrazolium chloride in pH 7.4 buffer. Tetrazolium reacts with NADH and dehydrogenase enzymes and causes all tissue still having the enzymes and cofactors to stain a deep red color. The infarcted area of the heart remains unstained.
After staining was completed, the slices were immersed in 10% Formalin to enhance the contrast of the stain. The slices were then sandwiched between two glass plates to a uniform 2-mm thickness. The region of infarcted tissue and the risk zone were traced, and the area of infarct and risk zone were determined by planimetry of the tracings. The volume of infarcted myocardium and myocardium at risk was calculated by multiplying the planimetered areas by the slice thickness.
Chemicals
Staurosporine and polymyxin B were obtained from Sigma Chemical (St. Louis, MO) and Calbiochem (San Diego, CA), respectively. Staurosporine was dissolved in dimethyl sulfoxide (DMSO, 100 kg/ml); this solution was further diluted in isotonic saline immediately before use. Polymyxin was dissolved in normal saline. Phorbol 12-myristate 13-acetate (PMA, Sigma P 8139) and 1-oleoyl-2-acetyl glycerol (OAG, Sigma 0 8255) were were dissolved in DMSO. OAG was dissolved in DMSO to a concentration of 0.4 mg/ml, and PMA was dissolved in DMSO to a concentration of 1.5 kg/ml. For each experiment 50 ~1 of the OAG solution or 20 ~1 of the PMA solution were diluted with oxygenated buffer and delivered to the perfusion line as a 5-min infusion.
Experimental Protocol
In uiuo study. Six groups were studied, all subjected to 30 min regional ischemia induced by occluding a coronary artery followed by 3 h of reperfusion.
Two groups were ischemically preconditioned with 5 min of coronary branch occlusion and 10 min reperfusion.
Either staurosporine at 50 kg/kg (n = 5) or polymyxin B at 24 mg/kg (n = 8) was given 5 min before the 30-min ischemic insult. Two other groups (n = 5 each) served as nonpreconditioned control groups and received either staurosporine or polymyxin B 5 min before a 30-min period of regional ischemia. The two final groups consisted of contemporary control groups that experienced only the 30-min ischemia (n = 3) or preconditioning plus 30 min ischemia (n = 3). This dose of staurosporine or polymyxin B was chosen as one which caused a brisk hypotensive response, a known effect of protein kinase C blockade.
In vitro study. This protocol included six groups. A control group (n = 12) was subiected onlv to 30 min regional ischemia with no pretreatment.
In the second and third groups, protein kinase C activators, PMA (0.05 nmol/5 min, n = 8) and OAG (50 nmol/5 min, n = 8) were infused into the perfusion line for 5 min followed by a lo-min washout period before the onset of regional ischemia, respectively. Both of these protein kinase C activators are coronary constrictors, and we chose a dose that gave only a minimal coronary constriction. We also tested whether polymyxin B could block preconditioning in the isolated heart model. In the fourth and fifth groups, polymyxin B was added to the Krebs buffer (50 PM) starting 5 min before the 30-min regional ischemia and continuing for 35 min. Hearts in the fourth group were preconditioned with 5 min global ischemia followed by 10 min reperfusion, and hearts in the fifth group were not preconditioned.
A final group of five hearts was preconditioned as above but in the absence of any drug.
Statistics
Values are presented as means 2 SE. One-way analysis of variance combined with a Newman-Keuls post hoc test was used to test for differences between the groups. A P value < 0.05 was considered significant.
RESULTS
In Situ Studies, Protein Kinase Inhibition
This protocol examined whether two known inhibitors of protein kinase C, staurosporine (50 pg/kg) or polymyxin B (24 mg/kg), could block preconditioning. Figure 1 , A-C, summarizes the hemodynamics for the four drug-treated groups. Staurosporine was administered as an intravenous injection and resulted in an immediate decrease in mean blood pressure, which persisted throughout the study (Fig. 1A) . No effect on heart rate was seen with staurosporine ( Fig. 1B) . Polymyxin B also caused hypotension, which again persisted throughout the study (Fig. 1C) . Unlike the staurosporine, polymyxin B did cause a slight but significant bradycardia, which also persisted (Fig. 10) . Hemodynamic data are not shown for the six untreated hearts.
In Fig. 2A infarct size is plotted against risk zone size. Note that data points from all four groups cluster in the same region of the graph, indicating that the relationship between infarct size and risk zone was similar in those groups. Protection would be indicated by points displaced down and to the right. Thus both staurosporine and polymyxin B completely blocked protection from preconditioning. Risk zone sizes and other related data for these animals appear in Table 1 . Figure 2B presents infarct size normalized as a percentage of the area at risk. Figure 2 , Left, shows the untreated hearts. Note that preconditioning resulted in much smaller infarcts. Regional ischemia in nonpreconditioned hearts treated with staurosporine or polymyxin B resulted in 40.5 t 2.8 and 42.0 t 7.0% infarction of the risk zone, respectively. Staurosporine or polymyxin B, however, blocked protection in preconditioned hearts with 36.2 t 2.7 and 40.9 t 2.5% of the risk zone infarcted, respectively. Infarcts were significantly smaller in the untreated-preconditioned group (7.3 t 2.7%, P < 0.01) than in the other five groups. There were no significant differences among the five other groups, indicating that preconditioning could not protect these Hearts were preconditioned at time 0 by 5 min regional ischemia followed by reperfusion.
hearts in the presence of the inhibitors. Infarct size in both of the protein kinase C blocked but nonpreconditioned groups are virtually identical to that seen in nonpreconditioned control hearts (37.8 t 3.1%), indicating that the inhibitors had little effect on infarct size in the absence of preconditioning.
In Vitro Studies, Protein Kinase C Activation Risk zone size, heart weight, rabbit weight, as well as initial coronary flow and left ventricle pressures, were not different among the six groups examined ( Table 2) . Activation of protein kinase C by both PMA and OAG resulted in a modest decrease in coronary flow and left ventricular developed pressure during the preischemic perfusion (Fig. 3, A and 23 In Fig. 4A , infarct size is plotted against the corresponding risk zone size for each of the hearts in the in vitro groups 1-3. Control hearts showed a significant linear correlation between infarct size and risk zone size (r = 0.90>, and the relationship was similar to that seen for the nonpreconditioned hearts studied in vivo in Fig.  2A . Both PMA and OAG consistently caused points to fall below that line. Figure 4B shows infarct sizes, when expressed as a percentage of the area at risk, for the six in vitro groups. Note that infarct size in nonpreconditioned hearts averaged 28.0 t 4.5% of the risk zone, which was somewhat smaller than that seen in the in vivo model, suggesting some model differences. Infarct size by this analysis was also significantly decreased by both PMA (6.4 t 1.4%) and OAG (11.7 t 3.3%) treatment compared with the nonpreconditioned.
We also tested whether polymyxin B could block protection from ischemic preconditioning in the Krebsperfused hearts. Preconditioning with 5 min global ischemia plus 10 min reperfusion resulted in only 11.8 t 2.2% of the risk zone infarcted (P < 0.05 vs. control). Note that the degree of protection afforded by OAG or PMA was virtually identical to that of ischemic precondi- tioning. Polymyxin B completely blocked protection from ischemic preconditioning (33.5 t 6.6% infarction) but had no effect on infarct size in the nonpreconditioned hearts (33.0 t 5.0% infarction, P = not significant against control).
DISCUSSION
In the present study evidence has been provided that protection by preconditioning against ischemia-induced necrosis is effected by activation of the protein kinase C cellular signaling pathway.
Inhibition of kinase activity abolished the protection afforded by preconditioning and activation of protein kinase C before regional ischemia reduced the extent of ischemia-induced necrosis. While none of these interventions by themselves would be conclusive proof of the involvement of protein kinase, taken together we believe that they strongly implicate this pathway.
To our knowledge this is the first report describing a protective role of protein kinase C against ischemia-induced necrosis. Staurosporine blocks protein kinase by interfering with the ATP binding site of the enzyme thus prevent- ing protein kinase C-dependent phosphorylation. While this makes staurosporine an excellent inhibitor of protein kinase C, its selectivity against other kinases, such as adenosine 3',5'-cyclic monophosphate (cAMP)-dependent kinase, is poor. Polymyxin B, on the other hand, competes with binding of the cofactor phosphatidylserine at the allosteric control site to inhibit the enzyme activity (5, 26). As a result, polymyxin B has no known effect on CAMP-dependent kinase. The common denominator of both interventions is inhibition of protein kinase C.
Protein kinase C when activated results in contraction of vascular smooth muscle. Thus blockade of pro- enzymes, and cytoskeletal components. Possible target proteins to effect the protection could include Ynucleotidase (11, lZ), a cytoskeletal element such as vinculin (I), or potassium channels (8, 30, 31) . Obviously, the present study offers no insight as to what that protein might be. The delayed K+ current seems to be enhanced by protein kinase C activation in the guinea pig heart (8, 30) , and the protein kinase C phosphorylation site on this membrane channel appears to be different from the CAMP-dependent phosphorylation site. The relationship between protein kinase C, Na+-H+ exchange, and Ca2+ channels in the heart is less clear but inhibitors of either the exchanger or channel blocks the functional response to PMA and OAG in the rat heart (9). Activation of phospholipase C causes the breakdown of phosphatidylinositol4,5 bisphosphate and phosphatidyl choline in the membrane with the resulting formation of DAG. DAG causes both activation of protein kinase C that is in the membranes and a translocation of inactive cytosolic protein kinase C into the membranes where it becomes active. Translocation is relatively slow and is thought to account for the delayed response often seen with protein kinase C activation, since most of the kinase resides in the cytosol of the quiescent cell. Strasser et al. (25) recently reported that translocation of protein kinase C from the cytosolic to the particulate fractions of the heart occurred in acute myocardial ischemia in the rat and that this translocation was independent of a-adrenergic receptors. A likely candidate for the cause of that translocation would be cardiac Al adenosine receptors, which are occupied during ischemia and reportedly can also activate phospholipase C (13). With the combination of the present data and results from previous studies in the rabbit (17, 29>, we propose I that adenosine receptor activation during ischemic preconditioning activates protein kinase C. A likely scenario would be for receptor activation during preconditioning to initiate translocation of protein kinase C into the membranes. During the second occlusion protein kinase C would be in place, and kinase activity could begin immediately upon reactivation of Al receptors. Protection was blocked by both of the inhibitors, even though treatment was started after the preconditioning ischemia. That observation indicates that protection requires phosphorylation of protein during the long ischemic period rather than during the preconditioning ischemia. Furthermore, the inhibitors had no discernable effect on infarct size in the nonpreconditioned hearts. Both of these observations indicate that protein kinase C was only active in hearts that had been subjected to ischemic preconditioning. The translocation theory explains those observations. Nonpreconditioned hearts would have minimal protein kinase C activity, since little enzyme would be in the membranes at the onset of ischemia. In the preconditioned hearts the critical period of phosphorylation of proteins would be during the long ischemia rather than the preconditioning ischemia.
Stimulation of protein kinase C with PMA or OAG both translocates protein kinase C from the cytoplasm tein kinase C in vivo would be expected to cause some peripheral dilation. Vasodilatation has indeed been described as the main hemodynamic response to staurosporine in vivo (3), and in the present study the hypotensive response to both staurosporine and polymyxin B was presumed to be caused by vasodilation.
Inhibition of serine phosphatases with okadaic acid should also increase protein phosphorylation by protein kinase C. Indeed, okadaic acid is reported to be very protective in an ischemic myocyte model (1). Cellular components that could be candidates for phosphorylation by protein kinase C include ion channels, receptors, PROTEIN KINASE C MEDIATES ISCHEMIC PRECONDITIONING Hl151 to the membranes and increases its phospholipid and calcium affinity (4, 10, 34) . In the heart q-adrenergic stimulation of phosphatidylinositol 4,5 bisphosphate hydrolysis increases tissue DAG as well as mechanical function. Phorbol esters and DAG on the other hand usually decrease heart function in a concentrationdependent manner. Recently, positive inotropic effects of PMA have also been demonstrated with doses in the picomolar range (33). In the present study we chose a dose of PMA and of OAG that would cause minimal constriction of the coronary arteries and changes in contractility. We believe that the reductions in flow that resulted were too small to ischemically precondition the heart but rather we propose that the protection derived from a direct activation of protein kinase C by the compounds. It is interesting to note that norepinephrine exposure has also been shown to mimic preconditioning in the rabbit heart (27). Norepinephrine is known to couple to protein kinase C through q-receptors and indeed blockade of those receptors removed the protection in that study (27) .
In conclusion, protein kinase C-dependent phosphorylation was found to be necessary for the protection to be realized from ischemic preconditioning.
In addition, protein kinase C activators could mimic preconditioning. We propose that protein kinase C is activated through a cellular signaling pathway involving adenosine Al receptors and G protein stimulated phospholipase C activity. It remains to be determined which protein is phosphorylated to protect the ischemic heart.
